Joseph J Buggy

US Patent:

6991915, Jan 31, 2006

Filed:

Jul 26, 2002

Appl. No.:

10/202879

Inventors:

Craig Hill - Burlingame CA, US
Joseph Buggy - San Carlos CA, US

Assignee:

Applera Corporation - Norwalk CT

International Classification:

C12Q 1/42
C12N 9/16

US Classification:

435 21, 435196

Abstract:

The present invention provides modified Cdc14 phosphatase proteins, and novel constructs for expression thereof, in which the sequence C-terminal to the catalytic domain has been deleted. This modification results in the expression of a single form of the enzyme, enabling purification of a homogeneous preparation of active enzyme at a high yield.

US Patent:

7045126, May 16, 2006

Filed:

Sep 16, 2004

Appl. No.:

10/941947

Inventors:

Joseph Buggy - San Carlos CA, US

Assignee:

Applera Corporation - Norwalk CT

International Classification:

A61K 38/46
C12N 9/16
C12N 1/20
C12N 15/00
C07H 21/04

US Classification:

424 946, 435196, 4352523, 4353201, 536 232

Abstract:

The present invention is directed to novel nucleic acids that encode novel HDAC proteins, which have an affect on chromatin structure and transcription. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods of producing the polypeptides of the present invention. Further provided by the present invention are methods of identifying novel compositions which mediate HDAC8 and the use of such compositions in diagnosis and treatment of disease.

US Patent:

7276612, Oct 2, 2007

Filed:

Apr 6, 2004

Appl. No.:

10/818755

Inventors:

Eric J. Verner - Foster City CA, US
Martin Sendzik - San Mateo CA, US
Chitra Baskaran - Foster City CA, US
Joseph J. Buggy - San Carlos CA, US
James Robinson - Sacramento CA, US

Assignee:

Pharmacyclics, Inc. - Sunnyvale CA

International Classification:

C07D 307/78
A61K 31/34

US Classification:

549467, 5142312, 5142521, 514350, 514383, 514396, 514406, 514419, 514423, 514443, 514469, 544166, 544336, 546229, 546298, 546336, 5482622, 5483351, 548491, 548537, 548560, 548565, 549 57, 549468

Abstract:

The present invention is directed to certain hydroxamate derivatives that are useful in the treatment of hepatitis C. These compounds are also inhibitors of histone deacetylase and are therefore useful in the treatment of diseases associated with histone deacetylase activity. Pharmaceutical compositions and processes for preparing these compounds are also disclosed.

US Patent:

7420089, Sep 2, 2008

Filed:

Aug 6, 2007

Appl. No.:

11/834558

Inventors:

Erik J. Verner - Belmont CA, US
Martin Sendzik - San Mateo CA, US
Chitra Baskaran - Foster City CA, US
Joseph J. Buggy - Mountain View CA, US
James Robinson - Sacramento CA, US

Assignee:

Pharmacyclics, Inc. - Sunnyvale CA

International Classification:

C07C 259/04
C07C 239/00
A61K 31/215
A61K 31/19

US Classification:

562622, 560312, 514507, 514575

Abstract:

The present invention is directed to certain hydroxamate derivatives that are useful in the treatment of hepatitis C. These compounds are also inhibitors of histone deacetylase and are therefore useful in the treatment of diseases associated with histone deacetylase activity. Pharmaceutical compositions and processes for preparing these compounds are also disclosed.

US Patent:

7820711, Oct 26, 2010

Filed:

Jul 18, 2007

Appl. No.:

11/779743

Inventors:

Joseph J. Buggy - Mountain View CA, US
Sriram Balasubramanian - San Carlos CA, US

Assignee:

Pharmacyclics Inc. - Sunnyvale CA

International Classification:

A61K 31/40

US Classification:

514412, 514414, 514416

Abstract:

Described herein are methods for treating a subject suffering from a T-cell lymphoma by administering to the subject a pharmaceutical composition containing a therapeutically effective amount of a selective inhibitor of histone deacetylase 8. Also described herein are methods for treating a subject suffering from a T-cell lymphoma by administering to the subject a population of autologous T-cells that have been exposed to a selective HDAC8 inhibitor composition ex vivo.

US Patent:

7834054, Nov 16, 2010

Filed:

Feb 26, 2009

Appl. No.:

12/393923

Inventors:

Erik J. Verner - Belmont CA, US
Joseph J. Buggy - Mountain View CA, US

Assignee:

Pharmacyclics, Inc. - Sunnyvale CA

International Classification:

A61K 31/34

US Classification:

514469

Abstract:

The present invention is directed to certain hydroxamate derivatives that are useful in the treatment of hepatitis C. These compounds are also inhibitors of histone deacetylase and are therefore useful in the treatment of diseases associated with histone deacetylase activity. Pharmaceutical compositions and processes for preparing these compounds are also disclosed.

US Patent:

7838234, Nov 23, 2010

Filed:

Jan 30, 2008

Appl. No.:

12/022977

Inventors:

Joseph J. Buggy - Mountain View CA, US
Sriram Balasubramanian - San Carlos CA, US

Assignee:

Pharmacyclics, Inc. - Sunnyvale CA

International Classification:

C12Q 1/68

US Classification:

435 6, 435 71

Abstract:

Described herein are methods and compositions for determining whether a particular cancer is resistant to or susceptible to a histone deacetylase inhibitor or to histone deacetylase inhibitors. The methods include analysis of the expression levels of at least four biomarker genes associated with response to a histone deacetylase inhibitor. Also described herein are methods and compositions for increasing the likelihood of a therapeutically effective treatment in a patient, comprising an analysis of the expression levels of at least four biomarker genes associated with response to a histone deacetylase inhibitor. Also described herein are isolated populations of nucleic acids derived from a cancer sensitive to or resistant to a histone deacetylase inhibitor. Further described are kits and indications that are optionally used in conjunction with the aforementioned methods and compositions.

US Patent:

8026371, Sep 27, 2011

Filed:

Oct 1, 2010

Appl. No.:

12/896535

Inventors:

Erik J. Verner - Belmont CA, US
Martin Sendzik - San Mateo CA, US
Chitra Baskaran - Foster City CA, US
Joseph J. Buggy - Mountain View CA, US
James Robinson - Sacramento CA, US

Assignee:

Pharmacyclics, Inc. - Sunnyvale CA

International Classification:

C07D 263/54
A61K 31/42

US Classification:

548217, 514375

Abstract:

The present invention is directed to certain hydroxamate derivatives that are useful in the treatment of hepatitis C. These compounds are also inhibitors of histone deacetylase and are therefore useful in the treatment of diseases associated with histone deacetylase activity. Pharmaceutical compositions and processes for preparing these compounds are also disclosed.